Orion Oyj (OTCMKTS:ORINY) Reaches New 12-Month Low at $17.50

Orion Oyj (OTCMKTS:ORINY)’s stock price reached a new 52-week low on Monday . The stock traded as low as $17.50 and last traded at $17.50, with a volume of 69 shares changing hands. The stock had previously closed at $17.50.

Orion Oyj Price Performance

The company has a current ratio of 3.10, a quick ratio of 1.59 and a debt-to-equity ratio of 0.21. The company has a market cap of $4.94 billion, a price-to-earnings ratio of 20.83 and a beta of 0.23. The business has a fifty day moving average price of $19.07 and a two-hundred day moving average price of $20.20.

Orion Oyj (OTCMKTS:ORINY) last released its quarterly earnings data on Tuesday, February 13th. The company reported $0.29 earnings per share for the quarter. The firm had revenue of $345.76 million for the quarter. Orion Oyj had a net margin of 17.74% and a return on equity of 26.81%. On average, equities analysts predict that Orion Oyj will post 0.89 earnings per share for the current year.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.